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INTRODUCTION
Malignant triton tumor (MTT) is a subtype of malignant
peripheral nerve sheath tumor (MPNST) characterized by the
presence of rhabdomyosarcomatous elements in a back-
ground of Schwannoma cells [1,2]. The tumor presents as a
painful or painless firm enlarging mass in a variety of
locations including the trunk, extremities, and head and neck
[3,4]. Often large and medium nerves such as the sciatic
nerve, spinal root, lumbosacral plexus, brachial plexus, and
cranial nerves are affected [1,2]. This rare tumor with fewer
than 100 cases reported in the literature, generally affects
adult patients but can also occur in children [5]. Although
MTT can present as a sporadic tumor, approximately 60–
70% occurs in young patients with neurofibromatosis type 1
(NF1) [2]. The tumor is highly malignant with a 5-year
survival rate of only 10–20% [2]. Outcome data is limited,
but suggests that complete tumor resection appears to
improve survival. A beneficial role for adjuvant chemother-
apy and radiation has not been established [4].
We herein describe the occurrence of MTT in a patient
with Li-Fraumeni syndrome (LFS). Although a variety of
soft-tissue sarcomas occur inLFS patients,MTThas not been
previously reported in this syndrome. A novel germline
mutation in TP53 tumor suppressor gene was identified in
this patient. Moreover, somatic mutations in p53 are
frequently encountered in a majority of MPNST/MTT
samples [6–10]. These findings implicate a role for p53
deregulation in the pathogenesis of this aggressive tumor.
Surgical resection could not be undertaken in this patient and
he was successfully treated with intensive chemotherapy for
induction, irradiation for local control, and high-dose
chemotherapy with autologous stem cell transplantation for
consolidation. He is alive without evidence of disease
recurrence at 43 months from diagnosis.
CASE
A 3-year-old boy was referred to the University
of Michigan Pediatric Hematology-Oncology clinic after a
4-week history of an enlarging, painless swelling within the
left cheek. There was no history of recent trauma or dental
infection. The family history was significant for a sister
diagnosed with low-grade adrenocortical carcinoma at
2 years of life, a mother with breast cancer at 36 years of
age and a prior history of thyroid cancer in her 20s, amaternal
grandmother with thyroid cancer in her 40s, and a maternal
grandfather with skin cancers and lymphoma. Therewas also
a family history of gastric cancer in a maternal great-aunt
(Fig. 1).
On physical examination, the patient was normal in
appearance. There was a firm, nontender mass measuring
approximately 6 cm in diameter locatedwithin his left cheek.
Under his left buccal mucosa was a white colored tumor.
There was no palpable cervical lymphadenopathy. The
patient did not have any physical stigmata of NF1 such as
neurofibromas, café-au-lait spots, axillary or inguinal freck-
ling, or Lisch nodules.
We report a 3-year-old boy with a malignant triton tumor (MTT)
involving the left masticator space with local invasion and regional
lymph node metastasis. Family history and detection of a novel
germline TP53 mutation confirmed his diagnosis of Li Fraumeni
syndrome (LFS). MTT has not been previously described in
association with LFS. This case along with a comprehensive review
of the literature, illustrate the importance of both somatic and
germline TP53 mutations in the pathogenesis MTT. The tumor could
not be resected and he was successfully treated with intensive
induction chemotherapy, irradiation, and high-dose chemotherapy
with autologous stem cell transplantation. Pediatr Blood Cancer
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Maxillofacial and neck CT scans demonstrated a
5.5 3 5 cm mass centered in the left masticator space
with extension and invasion into the left maxillary sinus,
lateral oral cavity, parapharyngeal fat space, and orbital
space. Destruction of multiple facial bones was also noted
(Fig. 2A). There was no intracranial extension. Enlarged
pathologic appearing lymph nodes in the region of the left
submandibular gland were present. Staging body CT scans,
bone scan, and bone marrow biopsies were negative for
distant metastatic disease.
Biopsy and histologic examination of the tumor revealed a
malignant neoplasm composed of intersecting fascicles of
variably pleomorphic spindle cells. The malignant cells
showed predominantly oval nuclei with granular chromatin
and prominent nucleoli (Fig. 3A). In selected areas,markedly
enlarged and occasional multinucleated cells were observed
(Fig. 3B). Immunohistochemical stains showed subsets of
tumor cells positive for S-100 protein, including the most
pleomorphic and multinucleated cells (Fig. 3C). Another
subset of tumor cells, generally less pleomorphic, was
positive for actin HHF-35 (Fig. 3D). Scattered tumor cell
nuclei were positive for myogenin. The malignant cells were
negative for melanoma marker Melan-A, epithelial mem-
brane antigen, and pan keratin. These immunohistologic
findings established the diagnosis of MTT.
To test for a TP53mutation, a blood specimen was sent to
the University of Minnesota Medical Center-Fairview
Diagnostic Laboratory. Leukocyte DNA was extracted and
polymerase-chain-reaction (PCR) was used to amplify exons
4–10 of the gene. PCR amplified DNA fragments were
sequenced using an Applied Biosystems 3100 analyzer.
Comparison of the patient’s sequence with the wild type
TP53 sequence showed a deletion of GTat 686–687 in exon
7. This heterozygous frameshift mutation is predicted to
introduce a premature stop codon at amino acid 238 by
altering the preceding 229–237 amino acids.
The tumor was deemed unresectable and the patient
received intensive induction chemotherapy, consisting of
courses of vincristine, doxorubicin, and cyclophosphamide
alternatingwith ifosfamide and etoposide administered every
3 weeks over 48 weeks. The doxorubicin was co-adminis-
tered with dexrazoxane for cardio-protection. The patient
also received 70.2 Gy of radiation for local control at week
12. As consolidation therapy, the patient was enrolled on a
clinical research study using high-dose chemotherapy with
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Fig. 1. A classic Li-Fraumeni syndrome pedigree showing multiple
familymembers with cancers, a young age at onset ofmalignancies, and
multiple primary cancers in an affected individual. The proband (arrow)
was tested and found to have a TP53 mutation. Other family members
have not been tested. It is unclear from the family history whether the
mutation originated from the maternal grandfather or maternal grand-
mother. Squares, males; Circles, females; Diamond with numbers,
individuals of unspecific sex; Shaded, diagnosed with cancer; Slash,
deceased; GC, gastric cancer; SC, skin cancer; LM, lymphoma; TC,
thyroid cancer; BC, breast cancer; MTT, malignant triton tumor; AC,
adrenocortical carcinoma. Numbers indicate age at tumor diagnosis.
Fig. 2. Axial images from maxillofacial computed tomography scans. (A) At diagnosis the large tumor invaded and eroded through adjacent
structures. (B) Three months after autologous stem cell transplant, the primary tumor had significantly decreased in size (arrows). A residual mass,
which is stable in size and PET negative remains and is presumed to be scar tissue.
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thiotepa and carboplatin followed by autologous stem cell
rescue for poor-prognosis, rare cancers. The patient tolerated
the therapies well without significant complications. His end
of therapy evaluation showed an 85% reduction in size of the
primary tumor (Fig. 2B). Forty-three months from diagnosis,
the patient continues in remission.
DISCUSSION
LFS is a rare autosomal dominant cancer predisposition
syndrome. It is a highly penetrant disorder associated with a
50%cancer risk by age 40 years and up to 90%by age 60 [11].
LFS patients often develop multiple primary cancers at a
young age. Additionally, these patients are at risk for a wide
range of malignancies, with a particularly high occurrence of
osteosarcomas, soft-tissue sarcomas, premenopausal breast
cancer, brain tumors, adrenocortical tumors, and acute
leukemias [11–14]. A variety of other cancers have been
reported at a lower rate in LFS patients. In this report, we
describe a pediatric patient with MTT and LFS with a novel
TP53 tumor suppressor gene mutation. Although the
association of MTT with a germline TP53 mutation in
humans has not been observed previously, our experience and
a review of the literature suggest that deregulation of p53
may be important in the pathophysiology of MPNST/MTT
[6–10].
TP53 tumor suppressor gene mutations are commonly
encountered in human cancers. Over 60% of families with
LFS have identifiable germline mutations in this gene [14].
Additionally, in some LFS patients and families with a
clinical diagnosis of LFS where a TP53 mutation is not
detected, germline mutations in the CHK2 gene that encodes
a protein product involved in p53 phosphorylation can be
found [15]. Sporadic tumors likewise frequently (>50%)
harbor TP53 mutations and the presence of such mutations
often denote a more aggressive phenotype [7,8,14]. The
TP53 gene located at chromosome band 17p13 spans 20 kb
and consists of one noncoding and ten coding exons. The
protein product is 393 amino acids in length with five highly
conserved domains. Functionally, the N-terminal region of
the protein contains a strong transcriptional activation
domain while the C-terminal region has a tetramerization
domain. In the intervening region, there is a sequence-
specific DNA binding domain (Fig. 4) [14,16]. The p53
protein forms a tetramer and serves as a transcription
activator of downstream targets involved in cell growth,
differentiation, and proliferation. Cellular stress and DNA
damage induces p53 accumulation within the nucleus to
cause cell cycle arrest and/or apoptosis [14]. A large number
of mutations have been identified throughout the gene,
however, the majority are missense mutations occurring
within theDNA-binding domain in exons 5–8 [14,15]. These
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Fig. 3. (H&E, 200) (A) Pleomorphic and multinucleated spindle cells comprise a portion of this neoplasm. (B) Variably pleomorphic but
generally more regular spindle cells comprise the majority of the neoplasm. (Immunoperoxidase, 200) (C) S-100 protein immunostain is positive
in a small subset of spindle cells and especially in the most atypical and multinucleated cells, identifying theMPNST component. (D) Muscle actin
HHF-35 is positive in a larger subset of spindle cells and occasional pleomorphic cells, identifying the rhabdomyosarcoma component.
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mutations result in reduced protein function and an inability
to maintain genomic integrity.
Our patient’s leukocytes harbored a heterozygous two
base pair deletion, GT, at nucleotides 686–687 in exon 7 of
the TP53 gene. A search through the p53 and LFSmutational
databases revealed that this deletional mutation has not been
previously observed. It is predicted to create a frameshift,
mutation altering amino acids 229–237 and introducing a
premature stop codon at amino acid 238. Interestingly, a
similar but not identical mutation (a deletion of two base
pairs at codons 209–210 that resulted in a premature stop
codon at amino acid 214 in exon 6) was reported by
Toguchida et al. in an 8-year-old girl with malignant fibrous
histiocytoma, a soft tissue sarcoma superficially resembling
MPNST, and a family history of tumors of neural-tissue
origin [17]. Based on models by Vogelstein et al., we
speculate that the truncation of 40% of the C-terminus of the
protein in our patient as a consequence of the deletional
mutation will not allow for oligomerization, resulting in
reduction of p53 tetramers, and decreased expression of
growth inhibitory genes and malignant transformation
(Fig. 4) [18].
A number of other studies have previously implicated
TP53 deregulation inMPNST/MTTmalignant transforma-
tion. Tumor samples from NF1-related and NF1-unrelated
MPNST/MTT cases have TP53 gene missense mutations,
loss of heterozygosity, or p53 nuclear accumulation
[7,8,10]. Leroy et al. and Zhou et al. showed that high-
grade MPNST had strong nuclear immunoreactivity for
p53 while neurofibromas did not, suggesting that nuclear
accumulation of p53may herald progression tomalignancy
[7,8]. More recently a causal role for p53 mutation and
MPNST/MTT development has emerged. Berghmans et al.
reported that zebrafishwithmissense germlinemutations in
the DNA-binding domain of tp53 developed MPNST at a
high rate. Embryos that harbored this mutation, failed to
undergo apoptosis in response to g radiation. The mutant
fish also failed to upregulate p21, a downstream target of
p53, and did not arrest at the G1/S checkpoint after
irradiation. These reports and our current case study,
together suggest that mutations in p53 appear to play a role
in the genesis of MPNST/MTT.
Clinically MTT is a highly malignant neoplasm with a
dismal prognosis and a 10–20% survival rate at 5 years [2].
Optimal management remains to be established because the
rarity of diagnosis has precluded a disease-specific long-
itudinal study. However, review of the literature shows that
like other soft tissue sarcomas, patients with MTT who
undergo a complete tumor resection fared better than those
who undergo incomplete resection [4,19]. Our patient
presented with a large MTT involving his left masticator
space with local invasion and regional metastatic disease.
Surgical expiration of the tumor would have been highly
morbid and, therefore, was not feasible for our patient. We
elected to treat him with induction chemotherapy designed
for Ewing’s sarcoma because the therapy included doxor-
ubicin and ifosfamide, agents known to be active against soft
tissue sarcomas generally and specifically against rhabdo-
myosarcoma and tumors of neural origin (doxorubicin for the
rhabdomyosarcoma component and ifosfamide for the
malignant Schwann cells). Radiation therapy was adminis-
tered during the chemotherapy course for local control and to
maximize dose intensity for our patient, we used high-dose
chemotherapy with autologous stem cell rescue for con-
solidation.Our patient remainswithout evidence of disease at
43 months from diagnosis. Although this approach proved
beneficial for our patient, the anecdotal nature of this finding
limits its clinical application.Additionally, this approachwas
undertaken for our patient with the recognition that this
therapy in the context of a germline p53 mutation as seen
in LFS may significantly increase the risk for a second
malignancy. Our patient, like other LFS patients, will require
annual comprehensive medical examinations.
In conclusion, we describe a 3-year-old boy with MTT
who was found to have a novel germline mutation in TP53.
Although the molecular mechanisms leading to the devel-
opment of MPNST/MTT have not been fully elucidated, our
findings support a role for p53 deregulation in MPNST/MTT
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Fig. 4. (A) Basic structure of the p53 protein consisting of 393 amino acids. Five highly conserved domains (I–IV) confer distinct functions as
described in the text. Solid arrow shows the location of the frameshiftmutation in our patient resulting in a truncated protein (B). The tetramerization
domain is lost.
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tumorigenesis. In patients presenting with MPNST/MTT,
physicians should not only look for physical signs ofNF1, but
also elicit a detailed medical and family history to evaluate
for LFS. Clinically, the treatment of MPNST/MTT remains a
challenge especially when the tumor cannot be completely
excised. Our patient’s tumor responded to intensive che-
motherapy which included autologous hematopoietic stem
cell transplantation and local irradiation. Given the aggres-
sive nature of this tumor, this therapeutic strategy may be
beneficial for other patients with MPNST/MTT as adjuvant
therapy to improve survival or neoadjuvant therapy to
facilitate tumor removal. This approach, however, should
be done in the setting of a clinical research study for rare
aggressive sarcomas.
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